Lorus Therapeutics (NASDAQ:APTO) Earns Daily Media Sentiment Rating of 0.28

News articles about Lorus Therapeutics (NASDAQ:APTO) (TSE:APS) have been trending positive this week, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Lorus Therapeutics earned a coverage optimism score of 0.28 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 43.9258574359243 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:

Shares of NASDAQ:APTO traded down $0.01 during midday trading on Friday, hitting $3.05. The stock had a trading volume of 117,295 shares, compared to its average volume of 436,864. The stock has a market capitalization of $97.02, a PE ratio of -5.87 and a beta of 2.32. Lorus Therapeutics has a fifty-two week low of $0.78 and a fifty-two week high of $3.97.

Several research firms have recently weighed in on APTO. HC Wainwright set a $6.00 price objective on shares of Lorus Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, March 28th. Zacks Investment Research raised shares of Lorus Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, February 13th. Finally, ValuEngine downgraded shares of Lorus Therapeutics from a “sell” rating to a “strong sell” rating in a report on Thursday, March 1st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. Lorus Therapeutics currently has a consensus rating of “Buy” and an average price target of $5.38.

COPYRIGHT VIOLATION NOTICE: “Lorus Therapeutics (NASDAQ:APTO) Earns Daily Media Sentiment Rating of 0.28” was first published by BBNS and is owned by of BBNS. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright & trademark law. The original version of this piece of content can be read at https://baseballnewssource.com/2018/04/06/positive-news-coverage-somewhat-unlikely-to-impact-aptose-biosciences-apto-share-price/2037783.html.

About Lorus Therapeutics

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Insider Buying and Selling by Quarter for Lorus Therapeutics (NASDAQ:APTO)

Receive News & Ratings for Lorus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lorus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 




Latest News

Teen Juan Soto Hits Home Run in First At-Bat
Teen Juan Soto Hits Home Run in First At-Bat
Ji-Man Choi Receives Another Chance in Milwaukee
Ji-Man Choi Receives Another Chance in Milwaukee
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Strikeouts Once Again Plaguing Cubs
Strikeouts Once Again Plaguing Cubs
Atlanta Braves: A Mix of Young and Old
Atlanta Braves: A Mix of Young and Old
Major League Baseball is Back and Astros Favored to Repeat
Major League Baseball is Back and Astros Favored to Repeat


Leave a Reply

 
© 2006-2018 BBNS.